Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V®

April 3, 2011 By Bio-Medicine.Org

NEW ORLEANS, April 3, 2011 /PRNewswire/ — A pooled analysis of
the SPIRIT II, III, IV and COMPARE trials presented today further
reinforces the positive clinical performance of Abbott’s (NYSE:
ABT
) market-leading XIENCE V® Everolimus Eluting
Coronary Stent System. As part of the analysis of all four trials,
two-year results on the safety and efficacy of XIENCE V compared to
TAXUS® Liberte® and TAXUS®
Express2™ Paclitaxel-Eluting Coronary Stent Systems (TAXUS)
were presented at the American College of Cardiology’s (ACC) 60th
Annual Scientific Session and i2 Summit 2011 in New Orleans.

In a presentation given by Dean J. Kereiakes, M.D., medical
director of The Christ Hospital Heart and Vascular Center in
Cincinnati, Ohio, predictors of artery re-blockage, cardiac death
or heart attack were evaluated out to two years in nearly 7,000
patients from the SPIRIT II, III, IV and COMPARE clinical trials.
The data demonstrated that use of XIENCE V resulted in
significantly lower clinical event rates following a stent
procedure. In the pooled analysis, XIENCE V demonstrated a 36
percent reduction in the risk of major adverse cardiac events
(MACE) compared to TAXUS (7.3 percent for XIENCE V versus 11.1
percent for TAXUS, p-value<0.001). MACE is an important
composite clinical measure of safety and efficacy outcomes for
patients, defined as cardiac death, heart attack (myocardial
infarction or MI), or retreatment of a lesion (ischemia-driven
target lesion revascularization, or ID-TLR).

“XIENCE V consistently demonstrated low adverse cardiac event
rates in trial after trial,” said Dr. Kereiakes. “The SPIRIT II,
III, IV, and COMPARE pooled analysis suggests that XIENCE V reduced
the occurrence of adverse events compared to patients treated with
the TAXUS stent. The low event rates demonstrated by XIENCE V in
these trials are esp

‘/>”/>

SOURCE

Related Articles Read More >

CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’
Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I

DeviceTalks Weekly.

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech